

Market Outlook

Nifty 50 ended the day at 24008 after gap down by more than 1% aimed India- Pakistan border tensions. The India VIX ended at 21.63. The Advance-Dcline Ratio is 0.28 , indicating Bearish trend. Derivatives data suggests Sideways to negative sentiments in the market for the coming sessions, with significant increase in CALL options OI data.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	24008.00	-1.10
SENSEX	79454.47	-1.10
BANKNIFTY	53595.25	-1.42
SMALLCAP	16085.65	-0.61

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-2591.56	-5.80%
Index Options	-28883.4	16.31%
Stock Futures	-1755.27	-1.21%
Stock Options	1250.08	4.34%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-3798.71	7858	10593
DII	7277.74	13741	41969

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
RELIANCE	10191308	12.51	-15.13
ICICIBANK	9814195	0.74	-11.86
POWERGRID	7166230	-1.61	-37.77
NTPC	6870260	-2.37	-20.75
HDFCBANK	6418433	5.76	-50.61
ITC	5824958	9.63	-58.74
AXISBANK	3659285	-4.88	-45.73
INFY	2995090	11.97	-46.84
KOTAKBANK	2785775	-10.9	-32.79
HDFCLIFE	2494080	18.55	5


NIFTY

Nifty	24065.50
OI (In contracts)	168264
CHANGE IN OI (%)	-1.23
PRICE CHANGE (%)	-0.85
IMPLICATION	LONG UNWINDING

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Build Up

Symbol	Price	Price %	OI	OI %
YESBANK	20.08	9.9	56147000 0	14.7
LUPIN	2042.8	1.1	8274750	6.8
UPL	678.5	3.5	28185355	4.0
SIEMENS	2846.6	0.6	2208000	3.8
SOLARINDS	13505	2.7	393000	3.1


BANKNIFTY

Banknifty	53732.00
OI (In lakhs)	60025
CHANGE IN OI (%)	-5.31
PRICE CHANGE (%)	-1.03
IMPLICATION	LONG UNWINDING

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Build Up

Symbol	Price	Price %	OI	OI %
M&MFIN	245.5	-3.8	23856000	6.9
DLF	633.2	-3.6	37140675	6.1
APOLLOTYRE	465.3	-4.1	7816600	5.9
SHREECEM	29215	-0.4	268375	5.4
INDHOTEL	721.95	-3.6	22308000	5.4

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
INDIGO	2814150	1978650	1.42
AARTIIND	9153600	7170000	1.28
JSL	1429875	1133825	1.26
BSE	3961625	3565875	1.11
MANAPPURAM	33288000	30609000	1.09
AUBANK	8491000	7989000	1.06
PATANJALI	1021500	967200	1.06
POONAWALLA	3446650	3324850	1.04
DALBHARAT	771925	763950	1.01
JUBLFOOD	3527500	3521250	1

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
SYNGENE	5065000	15523000	0.33
IDEA	536315350	1371106100	0.39
NTPC	18610500	47838000	0.39
ULTRACEMCO	737600	1820450	0.41
VBL	6805025	16223375	0.42
OFSS	257750	599750	0.43
HDFCLIFE	7459100	16909200	0.44
IRFC	27560300	62561700	0.44
APLAPOLLO	1299550	2909550	0.45
TITAGARH	1797075	3983125	0.45

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2279	2302	2257	2233	2211
ADANIPTS	1327	1345	1311	1293	1277
APOLLOHOSP	6836	6927	6764	6673	6601
ASIANPAINT	2350	2394	2295	2252	2196
AXISBANK	1169	1183	1160	1146	1137
BAJAJ-AUTO	7773	7846	7701	7628	7555
BAJAJFINSV	1995	2016	1980	1960	1944
BAJFINANCE	8781	8888	8704	8598	8521
BEL	324	332	315	308	299
BHARTIARTL	1871	1891	1855	1835	1819
CIPLA	1493	1502	1479	1470	1456
COALINDIA	386	388	382	379	375
DRREDDY	1170	1183	1153	1140	1123
EICHERMOT	5361	5390	5320	5292	5251
ETERNAL	230	233	227	224	220
GRASIM	2676	2714	2652	2614	2590
HCLTECH	1582	1592	1572	1562	1551
HDFCBANK	1917	1937	1905	1885	1874
HDFCLIFE	720	724	716	712	707
HEROMO-TOCO	3925	3994	3830	3761	3666
HINDALCO	637	645	622	614	600
HINDUNILVR	2357	2379	2331	2310	2284
ICICIBANK	1415	1436	1404	1383	1371
INDUSINDBK	829	839	816	806	793
INFY	1520	1527	1509	1502	1492

SYMBOL	R1	R2	PP	S1	S2
ITC	427	431	424	419	417
JIOFIN	252	256	247	244	239
JSWSTEEL	964	970	954	947	937
KOTAKBANK	2122	2137	2106	2091	2075
LT	3515	3574	3430	3371	3286
M&M	3047	3101	3006	2951	2911
MARUTI	12348	12437	12276	12187	12115
NESTLEIND	2339	2354	2317	2302	2279
NTPC	339	343	336	332	328
ONGC	238	240	234	231	227
POWERGRID	304	307	301	297	294
RELIANCE	1395	1408	1387	1375	1367
SBILIFE	1727	1748	1712	1692	1677
SBIN	775	785	758	749	732
SHRIRAMFIN	613	621	605	596	589
SUNPHARMA	1767	1783	1751	1734	1718
TATACONSUM	1127	1139	1107	1095	1075
TATAMOTORS	725	741	696	680	651
TATASTEEL	144	145	143	142	140
TCS	3460	3475	3434	3419	3393
TECHM	1504	1513	1495	1486	1477
TITAN	3590	3658	3475	3407	3292
TRENT	5207	5288	5142	5061	4996
ULTRACEMCO	11525	11662	11435	11298	11208
WIPRO	245	247	241	239	236

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results

Name	Email ID	Designation
Vishvajeet Singh	vishvajeet.singh1@religare.com	Research Analyst